Scholarlink

Background <p>To evaluate the dissemination and real-world implementation of recommendations from the 5th Edition of the Japanese Esophageal Cancer Practice Guidelines and to inform development of the upcoming 6th Edition, the Guideline Committee of the Japanese Esophageal Society conducted a nationwide Quality Indicator (QI) survey in Japan.</p> Methods <p>A nationwide, cross-sectional, web-based questionnaire survey was distributed to 381 certified institutions participating in the 2023 National Registry of Esophageal Cancer in Japan. Conducted in November 2024, the survey covered six domains—epidemiology, surgery, endoscopy, chemotherapy, radiation therapy, and pathology—reflecting key recommendations of the 5th Edition. Responses were summarized descriptively at the institutional level.</p> Results <p>Valid responses were obtained from 190 institutions (49.9%). Smoking cessation guidance was implemented in more than 90% of institutions, and over 90% also provided guidance on alcohol abstinence or moderation, although complete alcohol abstinence was less uniformly recommended. Minimally invasive, including robot-assisted, esophagectomy was adopted by over 90% of institutions. The proportion of institutions performing prophylactic cervical lymph node dissection varied by tumor location and stage, reflecting contemporary staging concepts. The DCF regimen was the predominant neoadjuvant therapy for stage II/III disease (94.7%), and immune checkpoint inhibitor–based chemotherapy was widely used for unresectable or recurrent disease. Advanced endoscopic diagnostic modalities, including magnifying and image-enhanced endoscopy, were widely adopted.</p> Conclusions <p>This nationwide QI survey demonstrates broad adherence to guideline-based multidisciplinary management of esophageal cancer in Japan and provides an evidence base for refining recommendations in the 6th Edition of the Japanese Esophageal Cancer Practice Guidelines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nationwide quality indicator survey on the current practice of esophageal cancer management in Japan: report from the guideline committee for the 6th edition of the Japanese Esophageal Cancer Practice Guidelines

  • 期刊论文

  • 发表日期：

    2026年5月13日

查看全文
  • Eisuke Booka,
  • Hiroya Takeuchi,
  • Ryu Ishihara,
  • Katsunori Iijima,
  • Hitoshi Ishikawa,
  • Yoshinori Ito,
  • Takashi Oyama,
  • Ken Kato,
  • Hirofumi Kawakubo,
  • Hiroshi Kawachi,
  • Yasue Kimura,
  • Shiko Kuribayashi,
  • Koji Kono,
  • Takashi Kojima,
  • Hiroshi Saeki,
  • Takahiro Tsushima,
  • Minako Fujiwara,
  • Tomoki Makino,
  • Satoru Matsuda,
  • Keiko Minashi,
  • Tatsuya Miyazaki,
  • Manabu Muto,
  • Yuji Murakami,
  • Takako Yoshii,
  • Toshiyuki Yoshio,
  • Taiki Yamaji,
  • Tomoki Yamatsuji,
  • Masahiro Yoshida

摘要

Background

To evaluate the dissemination and real-world implementation of recommendations from the 5th Edition of the Japanese Esophageal Cancer Practice Guidelines and to inform development of the upcoming 6th Edition, the Guideline Committee of the Japanese Esophageal Society conducted a nationwide Quality Indicator (QI) survey in Japan.

Methods

A nationwide, cross-sectional, web-based questionnaire survey was distributed to 381 certified institutions participating in the 2023 National Registry of Esophageal Cancer in Japan. Conducted in November 2024, the survey covered six domains—epidemiology, surgery, endoscopy, chemotherapy, radiation therapy, and pathology—reflecting key recommendations of the 5th Edition. Responses were summarized descriptively at the institutional level.

Results

Valid responses were obtained from 190 institutions (49.9%). Smoking cessation guidance was implemented in more than 90% of institutions, and over 90% also provided guidance on alcohol abstinence or moderation, although complete alcohol abstinence was less uniformly recommended. Minimally invasive, including robot-assisted, esophagectomy was adopted by over 90% of institutions. The proportion of institutions performing prophylactic cervical lymph node dissection varied by tumor location and stage, reflecting contemporary staging concepts. The DCF regimen was the predominant neoadjuvant therapy for stage II/III disease (94.7%), and immune checkpoint inhibitor–based chemotherapy was widely used for unresectable or recurrent disease. Advanced endoscopic diagnostic modalities, including magnifying and image-enhanced endoscopy, were widely adopted.

Conclusions

This nationwide QI survey demonstrates broad adherence to guideline-based multidisciplinary management of esophageal cancer in Japan and provides an evidence base for refining recommendations in the 6th Edition of the Japanese Esophageal Cancer Practice Guidelines.